Histological transformation in lung adenocarcinoma: Insights of mechanisms and therapeutic windows.

IF 4.7 2区医学 Q1 MEDICINE, GENERAL & INTERNAL

Journal of Translational Internal Medicine Pub Date : 2024-11-06 eCollection Date: 2024-11-01 DOI:10.1515/jtim-2024-0019

Nuopei Tan, Yan Li, Jianming Ying, Wanqing Chen

{"title":"Histological transformation in lung adenocarcinoma: Insights of mechanisms and therapeutic windows.","authors":"Nuopei Tan, Yan Li, Jianming Ying, Wanqing Chen","doi":"10.1515/jtim-2024-0019","DOIUrl":null,"url":null,"abstract":"<p><p>Histological transformation from lung adenocarcinoma (ADC) to small cell lung carcinoma (SCLC), large cell neuroendocrine carcinoma (LCNEC), squamous cell carcinoma (SCC), and sarcomatoid carcinoma (PSC) after targeted therapies is recognized as a mechanism of resistance in ADC treatments. Patients with transformed lung cancer typically experience a poor prognosis and short survival time. However, effective treatment options for these patients are currently lacking. Therefore, understanding the mechanisms underlying histological transformation is crucial for the development of effective therapies. Hypotheses including intratumoral heterogeneity, cancer stem cells, and alteration of suppressor genes have been proposed to explain the mechanism of histological transformation. In this review, we provide a comprehensive overview of the known molecular features and signaling pathways of transformed tumors, and summarized potential therapies based on previous findings.</p>","PeriodicalId":51339,"journal":{"name":"Journal of Translational Internal Medicine","volume":"12 5","pages":"452-465"},"PeriodicalIF":4.7000,"publicationDate":"2024-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11538883/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Translational Internal Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1515/jtim-2024-0019","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Histological transformation from lung adenocarcinoma (ADC) to small cell lung carcinoma (SCLC), large cell neuroendocrine carcinoma (LCNEC), squamous cell carcinoma (SCC), and sarcomatoid carcinoma (PSC) after targeted therapies is recognized as a mechanism of resistance in ADC treatments. Patients with transformed lung cancer typically experience a poor prognosis and short survival time. However, effective treatment options for these patients are currently lacking. Therefore, understanding the mechanisms underlying histological transformation is crucial for the development of effective therapies. Hypotheses including intratumoral heterogeneity, cancer stem cells, and alteration of suppressor genes have been proposed to explain the mechanism of histological transformation. In this review, we provide a comprehensive overview of the known molecular features and signaling pathways of transformed tumors, and summarized potential therapies based on previous findings.

查看原文本刊更多论文

肺腺癌的组织学转化：机制和治疗窗口的启示。

在接受靶向治疗后，肺腺癌（ADC）向小细胞肺癌（SCLC）、大细胞神经内分泌癌（LCNEC）、鳞状细胞癌（SCC）和肉瘤样癌（PSC）的组织学转化被认为是 ADC 治疗的一种耐药机制。转化型肺癌患者通常预后较差，生存时间较短。然而，目前还缺乏针对这些患者的有效治疗方案。因此，了解组织学转化的内在机制对于开发有效疗法至关重要。有人提出了包括瘤内异质性、癌症干细胞和抑制基因改变等假说来解释组织学转化的机制。在这篇综述中，我们全面概述了转化肿瘤的已知分子特征和信号通路，并根据以往的研究结果总结了潜在的疗法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Translational Internal Medicine MEDICINE, GENERAL & INTERNAL-

CiteScore

5.50

自引率

8.20%

发文量